Novartis Drug Flunks Phase 3 Test in Giant Cell Arteritis

Pharmalittle: We're reading about a memo on RFK Jr., a Novartis blockbuster's failed trial, and more

And so, another working week will soon draw to a close. Already, you say? Well, there is a holiday coming up on this side of the pond. So we are happily daydreaming about weekend plans. Our agenda is uncertain. We do plan, however, to hang with all of our short people, nosh on some favorite foods, and, yes, hold yet another listing party. This time around, the rotation will likely include this, this, this, this and this. And what about you? Ther…

Novartis fails in late-stage trial for Cosentyx in giant cell arteritis

Novartis drug flunks phase 3 test in giant cell arteritis

Novartis hopes of bringing Cosentyx to patients with giant cell arteritis seem to be over after the drug missed all the endpoints in a phase 3 trial.

Novartis provides update on Phase III GCAptAIN study of Cosentyx® in giant cell arteritis (GCA)

The GCAptAIN study did not meet its primary endpoint of sustained remission at Week 52 in adults with newly diagnosed or relapsing GCA1Safety in GCA patients was consistent with known safety profile of Cosentyx® (secukinumab)1